Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

This article originally appeared here.
Share this content:
Omalizumab Ups Efficacy of Multifood Oral Immunotherapy
Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

TUESDAY, Dec. 12, 2017 (HealthDay News) -- Omalizumab improves the efficacy of multifood oral immunotherapy among pediatric patients with multifood allergies, according to a study published online Dec. 12 in The Lancet Gastroenterology & Hepatology.

Sandra Andorf, Ph.D., from the Stanford University School of Medicine in California, and colleagues conducted a phase 2 clinical trial involving participants aged 4 to 15 years with multifood allergies. Participants were randomized to receive multifood oral immunotherapy to two to five foods together with omalizumab (36 participants) or placebo (12 participants); 12 individuals were included as controls and did not receive omalizumab or placebo. Omalizumab or placebo was administered for 16 weeks, with oral immunotherapy starting at week eight. The exit, double-blind, placebo-controlled food challenge was performed at week 36.

The researchers found that a significantly greater proportion of the omalizumab-treated versus placebo participants passed double-blind, placebo-controlled food challenges to 2 g protein for two or more of their offending foods at week 36 (83 versus 33 percent; odds ratio, 10.0). No serious or severe adverse events occurred. A significantly lower median per-participant percentage of oral immunotherapy doses associated with any adverse events was seen for participants in the omalizumab group (27 versus 68 percent). Gastrointestinal events were the most common adverse events in both groups.

"In multifood allergic patients, omalizumab improves the efficacy of multifood oral immunotherapy and enables safe and rapid desensitization," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Proinflammatory Diet Linked to Increased Colorectal Cancer Risk

Proinflammatory Diet Linked to Increased Colorectal Cancer Risk

Higher empirical dietary inflammatory pattern score linked to increased risk of CRC for men and women

Longer Duration of Post-Op Opioid Use Associated With Misuse

Longer Duration of Post-Op Opioid Use Associated With ...

Higher dose, shorter duration Rx may minimize risk of longer term misuse, authors say

Alcohol Induced DNA Repair Genes Prognostic in Gastric Cancer

Alcohol Induced DNA Repair Genes Prognostic in Gastric ...

BRF1, BRCA1/2, MPO induced by alcohol have prognostic value for patients with gastric cancer

is free, fast, and customized just for you!

Already a member?

Sign In Now »